Occuity ramps up IP for early detection of diseases through the eye

Company secures new funding and enhances ‘oculomics’ platform, filing new patent for non-invasive screening of diabetes.

UK-based MedTech company Occuity has raised £1.3 million in a Convertible Loan Note (CLN) investment round, and revealed it has achieved two key intellectual property milestones relating to its work using non-invasive optical devices for disease screening and monitoring. The company is focused on early detection and improved management of disease using ‘oculomics’ – leveraging data from the eye to enhance understanding of wider health issues.

The first milestone involves the filing of a patent relating to Occuity’s SD1 initiative to create a non-invasive screening tool for diabetes, a condition projected to impact 1.3 billion individuals by 2050. The newly filed patent safeguards the proprietary technology employed in the prototype SD1 diabetes screening device, which builds on the company’s existing PM1 and AX1 optical platforms.

Occuity recently demonstrated that its SD1 technology was effective in detecting levels of advanced glycation end-products (AGEs) in the eye. Elevated concentrations of AGEs can indicate the presence of diabetes or prediabetes.

“Screening for chronic diseases is something that I and the Occuity team are deeply passionate about; we hope to fundamentally change the approach to healthcare with a move toward preventative medicine,” said Dr Robin Taylor, CTO of Occuity. “This patent application is a huge step toward our long-term goal of achieving an easy-to-develop, cost-effective, screening tool for chronic diseases such as diabetes and Alzheimer’s disease.”

The second milestone marks the recent approval of a key patent, covering the high-speed, long-range scanning technology used across Occuity’s product portfolio. This patent encompasses the electro-mechanical design that enables precise linear scanning over an extended range at a rate of over 200 scans per second.

“The granting of this patent is crucial in protecting a key enabling technology that is fundamental to achieving our mission of assessing someone’s health by simply performing a quick scan of their eye,” added Taylor.

Occuity also reported the progression of four patents from initial UK filing to international filings, with two in the EU and US and two in the EU, US, China, and India.

Speaking about the recent patents, Dr Dan Daly, CEO of Occuity, said “They are vital components in our mission to use the eye as a window into the overall health of the body. It’s a testament to our potential in the field of optical scanning and eye health and advances our mission to transform disease detection, diagnosis, and management through non-invasive techniques.”

The CLN investment round will support the continued development of Occuity’s technology, as well as ramping up sales and marketing activities ahead of the launch of its first ophthalmic products next year.